biologic disease-modifying antirheumatic drugs

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry

OBJECTIVE: To describe the outcomes of MTX and biologic DMARD (bDMARD) treatment in patients with RA and assess unmet needs in patients …

Inge C. Olsen, Elisabeth Lie, Radu Vasilescu, Gene Wallenstein, Sander Strengholt, Tore K. Kvien